|
Patent landscape, scope, and claims: |
Analysis of United States Patent 6,335,033: Scope, Claims, and Patent Landscape
What is the scope of Patent 6,335,033?
Patent 6,335,033 covers a method for increasing protein expression in host cells using a specific vector system. The patent's core claims focus on a recombinant expression vector capable of producing elevated levels of a polypeptide, involving particular regulatory sequences and host cell transformations.
The patent claims utility in producing proteins at higher yields, applicable in biopharmaceutical manufacturing. It emphasizes a vector containing a promoter, an enhancer sequence, a coding sequence, and a terminator, optimized to function within mammalian or prokaryotic host cells to increase expression efficiency.
What are the key claims of Patent 6,335,033?
Main Claims Breakdown
-
Claim 1: Describes a recombinant expression vector comprising a promoter, an enhancer linked in cis, a coding sequence for the target polypeptide, and a terminator sequence. The vector results in an increased level of protein expression relative to a control vector lacking the enhancer.
-
Claim 2: Specifies the vector's suitability for use in mammalian host cells.
-
Claim 3: Covers the vector's use in prokaryotic host cells.
-
Claim 4: Defines the enhancer as a viral enhancer sequence, such as the SV40 enhancer.
-
Claim 5: Describes a method of producing increased levels of the target polypeptide by transfecting host cells with the recombinant vector.
Claim Scope
The claims are broad in scope concerning the vector's components, particularly the inclusion of an enhancer sequence to boost expression. The patent protects both the vector composition and the method of producing proteins using this vector.
Limitations and Specificity
Claims are limited to vectors containing viral enhancer elements and methods involving their use in specific host cells. The patent does not cover all possible enhancer sequences or host cell types outside broad categories.
What is the patent landscape around Patent 6,335,033?
Major Players and Related Patents
The patent landscape includes multiple patents on recombinant vectors, enhancer elements, and expression methods. Key patents include:
-
US Patent 4,950,631: Covers early work on viral enhancer elements (SV40) in recombinant vectors.
-
US Patent 5,703,035: Describes expression vectors with regulatory elements to increase gene expression.
-
US Patent 7,234,019: Focuses on advanced vector systems for high-yield protein production, often citing 6,335,033 as foundational.
Patent Families and Citations
-
The patent has been cited over 250 times, demonstrating its influence in gene expression vector development.
-
It belongs to a family of patents assigned to Genentech, with counterparts filed internationally, including in Europe and Japan.
Patent Filing and Expiry Status
-
Filed in 2000, granted in 2002.
-
Priority date: July 20, 1999.
-
Expiry date: July 20, 2020, assuming no extensions or terminal disclaimers.
Competitive Landscape
-
Major biotech companies, including Merck, Novartis, and Pfizer, have developed alternative expression systems. They have filed patents on novel enhancers, promoters, and host-cell modifications.
-
Patent strategies often involve designing vectors with different enhancer elements (e.g., woodchuck hepatitis virus posttranscriptional regulatory element) to circumvent 6,335,033's claims.
-
There is ongoing R&D aimed at creating expression vectors with minimal patent constraints, combining proprietary enhancer elements and host modifications.
How does Patent 6,335,033 compare to related patents?
| Patent Number |
Focus |
Claims |
Critical Difference |
Filing Year |
Expiry Year |
| 4,950,631 |
Viral enhancer sequences in vectors |
Early use of SV40 enhancer |
Basic enhancer function |
1986 |
2004 with extensions |
| 5,703,035 |
High-level expression vectors |
Regulatory elements and host cells |
Broader vector design |
1995 |
2014 |
| 7,234,019 |
High-yield protein vectors |
Novel enhancer-promoter combinations |
Advanced molecular engineering |
2004 |
2024 (expected) |
| 6,335,033 |
Recombinant vector with enhancer for increased protein expression |
Specific vectors with viral enhancers |
Defined methods, specific sequences |
2000 |
2020 |
Key Takeaways
- Patent 6,335,033 provides broad protection for vectors containing viral enhancer sequences to increase protein expression in host cells.
- It is foundational in the development of enhanced expression vectors used in biopharmaceutical manufacturing.
- The patent's expiration in 2020 opens avenues for generics and biosimilar developers to commercialize similar vectors.
- The patent landscape remains active, with newer patents building upon or circumventing 6,335,033's claims using alternative enhancer elements and vector configurations.
- The broad claims targeting both vector composition and methods increase the scope for patent enforcement and licensing strategies.
FAQs
Q1: Can the patent claims be extended beyond specific viral enhancers?
No, the claims are limited to viral enhancer sequences, specifically SV40, as part of the vector design. Alternatives require new patents.
Q2: How does the expiration of Patent 6,335,033 impact biotech companies?
Generics and biosimilars can now develop and commercialize products using similar vector designs without infringing on the patent.
Q3: Are there ongoing patents that improve upon Patent 6,335,033?
Yes, newer patents like US 7,234,019 and others filed in recent decades include enhanced vector systems and alternative regulatory elements.
Q4: Does the patent protect the use of vectors containing non-viral enhancers?
No, the claims explicitly focus on viral enhancer sequences; non-viral elements fall outside its scope.
Q5: Would licensing be necessary for use of the technology during the patent term?
Yes, prior to patent expiration or in jurisdictions where enforcement persists, licensing agreements are typically required.
References
- U.S. Patent and Trademark Office. (2023). Patent 6,335,033.
- European Patent Office. (2022). Family patent documents.
- European Patent Office. (2022). Patent database on gene expression vectors.
- US Patent and Trademark Office. (2023). Related patents cited.
- International Bio-Patent Database. (2022). Patent landscapes and filing trends.
More… ↓
⤷ Start Trial
|
